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not reduce DAF-16 levels or
nuclear localization and still
reduced lifespan in worms
expressing a constitutively nuclear
form of DAF-16. Nevertheless,
depletion of two SCF E3 ligase
F-box components (LIN-23 and
PHI-3) did prevent the increased
expression of genes activated by
DAF-16, suggesting that they
target cofactors that affect the
ability of DAF-16 to activate
longevity-promoting genes.
The results from Li et al. [6]
and Ghazi et al. [7] show that
ubiquitin-mediated proteolytic
regulation targets both DAF-16/
FOXO to limit lifespan and
additional factors to extend
lifespan. Moreover, it was recently
shown that inactivation of a
C. elegans F-box protein called
DRE-1 results in the precocious
expression of some cell fates
expressed during larval
development [15]. Larval
transitions in C. elegans are
temporally regulated and
reminiscent of aging but occur
earlier in life. Intriguingly, CUL-1 in
vertebrates targets FOXO family
members for degradation [16], and
it will of course be interesting to
learn whether ubiquitin-mediated
proteolysis influences lifespan and
aging in other animals.
In closing, the regulation of
longevity is complex and
multifaceted, and much remains
unknown [4]. For example,
reducing IIS doubles lifespan,
while removing the germline in
C. elegans IIS mutants results in
a remarkable sixfold increase
in lifespan [17]. In addition,
mitochondrial function influences
longevity, and the NAD-dependent
histone deacetylase Sir2 also
extends lifespan [4]. Each animal
genome includes hundreds of
genes that encode the machinery
of proteolysis; exactly how many
of them regulate lifespan remains
to be seen.
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A polymorphism modulating innate immunity signal transduction has
recently been shown to influence human susceptibility to many different
infections, providing onemore indication of the potential of host genetics
to reveal physiological pathways and mechanisms that influence
resistance to infectious diseases.
Jacques Fellay
and David B. Goldstein
A striking feature of all known
infectious diseases is that no
matter how devastating they may
be there is always variation among
humans in their susceptibility. In
the middle of the 14th century,
some people inexplicably survived
Black Death while their entire
villages were devastated [1]; in
African cities with a high
prevalence of HIV/AIDS, certain
prostitutes remain uninfected
after years of unprotected sexualcontact [2]; more prosaically,
some of us seem resistant to the
flu virus without ever having had
a vaccination.
A few of the underlying genetic
causes for this variation have
been shown to affect elements
of both innate and adaptive
immunity. Recent work has now
established solid evidence for
two hypotheses long suspected
but as yet with little empirical
evidence: first, that there are
intermediate levels of immune
response that are optimal, and
second, that some genetic
differences confer advantages
against a broad range of
infectious agents [3].
Dispatch
R517The strength of Darwinian
selection associated with
infectious disease is distressingly
clear. The Black Death, again, is
estimated to have killed between
a third and two-thirds of Europe’s
population in 3 years (1348–1350),
with a total number of victims
probably reaching 75 million [1];
the influenza epidemic of 1918
killed between 50 and 100 million
people worldwide (2.5–5% of the
human population at the time) [4].
Clearly these diseases (and untold
others not recorded by history)
have molded patterns of human
genetic variation. The search for
signals of infection-driven selection
in the human genome promise to
shed new light on genes involved in
crucial immunity pathways [5].
Classic examples of human
polymorphism relate to infectious
diseases. Erythrocyte polymorphic
variants associated with protection
againstmalariahave reachedastate
ofbalancedpolymorphism, inwhich
the deleterious consequences of
the homozygous status are
compensated, at the population
level, by the protection conferred by
the heterozygote status. Forerunner
in thisgroup,hemoglobinS,causing
sickle cell anemia in homozygous
individuals but highly protective
against Plasmodium falciparum in
heterozygous individuals, was
identified more than half a century
ago [6].
Even more noticeably, the major
histocompatibility complex region
(MHC), central to adaptive
immunity, contains the most
polymorphic set of genes
identified in humans, but at the
same time contains ancestral
alleles that have been conserved
for millions of years amongst
different primate species [7].
This testifies to the very potent
long-term action of balancing
selection in the region, most
probably maintained through
pressure from infectious diseases.
In this context, it is somewhat
surprising that, despite its long
tradition of genetic studies,
infectious disease genetics
suddenly finds itself almost left
behind. Proof-of-principle for the
value of large-scale genetic
studies is being established in
various fields of biomedical
research, with recent successesfor example in metabolic [8] and
inflammatory diseases [9].
However, as of this writing, there
has still not been a single
published whole-genome
association study that has
identified gene variants that
influence host response to an
infectious agent.
Yet another demonstration of the
insights afforded by host genetics
nowcomes froma recent candidate
gene study of a component of
the innate immunity signaling
pathways. Khor et al. [3] describe
a functional variant in a gene
called Toll–interleukin 1 receptor
domain-containing adaptor
protein (TIRAP) that associates
with protection against four
widespread infectious diseases,
which together constitute a major
cause of mortality all over the
world — invasive pneumococcal
disease, bacteremia, malaria and
tuberculosis.
At first glance, those diseases
are dissimilar enough to make the
finding of a common
‘susceptibility gene’ surprising.
But the result is convincing, and
the explanation is based on an
essential characteristic of the
innate immunity recognition
system: the convergence of
signaling pathways. Pattern
recognition receptors, and notably
Toll-like receptors (TLRs), are
located at the interface between
microbe and host and are
therefore responsible for the
first-line sensing of pathogens
and for the crucial discrimination
of non-self from self. After specific
detection of evolutionarily
conserved microbial structures,
they differentially activate signal
transduction pathways, leading to
inflammatory and immune
responses [10,11]. The key, it
seems, is to achieve the
appropriate level of immune
response once foreign molecules
are recognized.
Surface molecular structures
from all sorts of bacteria (notably
lipopolysaccharideand lipoteichoic
acid), from mycobacteria
(lipoarabinomannan) and also
from Plasmodium falciparum
(glycosylphosphatidylinositol)
[12] are recognized by the TLR2
and/or the TLR4 receptors.
Interacting with their intracellulardomain, both receptors share
a downstream adaptor protein,
the MyD88 adapter-like protein
(Mal), which is the product encoded
by the TIRAP gene [13]. Placed
at the crossroads between the
first-line receptors and a restricted
number of downstream
convergent molecules, Mal is
able to modulate the strength of
the signal following activation.
The Mal variant identified in the
new study [3] is an amino-acid
substitution (leucine for serine at
position 180,S180L). This rare allele
associates with a decrease
in signal-transduction efficiency
and, in heterozygous form, is
associated with protection
against infectious agents [3]. In
contrast, the very few patients
that are homozygous for the
S180L variant seem to be highly
susceptible to thesamepathogens,
probably because of failure in
specific immune signaling. This
sort of genetic model would
generally raise suspicions of
a ‘false-positive’ association. In this
case, however, the association
results are unusually strong
(indeed, the combined P-value
would survive correction in the
context of a genome-wide
association study using tagging
single nucleotide polymorphisms).
The authors also provide
a compelling explanation for the
genotypic effects. As has been
hypothesized many times, these
results suggest that an
intermediate state of activation of
the signaling cascade is optimal
to reconcile the goal of keeping
the body alert to fight infection,
while restraining the inflammatory
response that can, itself, be harmful
to the host. This proposal is
consistent with ‘heterozygote
advantage’: individuals
homozygous for the rare variant
mount too weak a response, while
the heterozygote response is
optimal [7].
The minor allele frequency of the
Mal S180L variant is very low,
except in patients of European
ancestry (approximately 0.15 in
Caucasians and 0.02 in Africans
and Asians, which is concordant
with frequencies observed in
HapMap samples). Consequently,
the fraction of global susceptibility
to each infection explained by this
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Infectious diseases Deaths in 2002 Percentage of all deaths
Lower respiratory infections 3.9 million 6.90%
HIV/AIDS 2.8 million 4.90%
Diarrheal diseases 1.8 million 3.20%
Tuberculosis 1.6 million 2.70%
Malaria 1.3 million 2.20%
Measles 0.6 million 1.10%
Pertussis 0.29 million 0.50%
Tetanus 0.21 million 0.40%
Meningitis 0.17 million 0.30%
Syphilis 0.16 million 0.30%
(Adapted from the WHO world report 2004.)single polymorphism remains low,
even though it is very significant
in heterozygous individuals (up to
50% reduction in susceptibility to
various major diseases). A low
explained fraction is an argument
in support of the idea that
susceptibility to infectious
diseases is highly polygenic:
many loci with modest effects (on
global susceptibility) are likely to be
involved. The logical conclusion is
that most of the inter-individual
variability has still to be uncovered.
Human susceptibility or
resistance to microbial attack can
be seen as the final result of
a dynamic interplay between the
genetic make up of the individual
host and the pathogen, with
environmental influences adding
another layer of complexity. In the
middle of such an intricate
picture, however, it is reassuring for
host genetics research that some
well-established examples
of human polymorphisms clearly
influence the outcome of various
infections. These polymorphisms
are located in genes that encode
cellular co-factors directly
implicated in the life cycle of
pathogens (such as the chemokine
receptor CCR5 [14]); proteins
involved in innate recognition of
microbes and first-line defense
innate immunity pathways (such
as the TLRs [15]); or molecules
that regulate adaptive immune
responses (most notably the HLA
region bearing the MHC class I and
II genes [16]). This functional
distribution makes sense but is
likely to be largely incomplete: the
vast majority of variants have
been found in candidate gene
studies, which can only test
a priori hypotheses, and even
these studies have generally beenincomplete: despite its
prominence, the HLA region is
normally only studied at the level
of allelic diversity represented by
classical HLA typing. Causal
variants in the region, such as those
influencing expression, would be
missed.
Infectious diseases remain
major killers today, especially in
less-developed countries (Table 1).
The fight against mortality and
morbidity due to common
pathogens has, by nature, to be
global, and certainly warrants
a much more dedicated effort
from the scientific community. As
we enter a new era of genomic
knowledge and technological
potential, there is a new hope that
large-scale association studies
will reveal important human genetic
components that could be targeted
by drugs or vaccines. It is time to
carry out comprehensive large-
scale host genomic analyses of all
the major infectious agents.
Together these pathogens are
responsible formore than 10million
deaths per year. Results such as
those fromKhor et al. [3]make clear
the importance of host genetics.
There is reason to be optimistic that
genome-wide association studies
will prove a key tool in the global
effort to reduce the morbidity and
mortality caused by these
diseases.
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